LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 9, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 23, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical

New Codes Expand Market Access to Treatment with the NanoKnife ® System LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 21, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer

LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

Multi-center, multi-national study to evaluate mechanical thrombectomy treatment in acute, intermediate-risk PE patients in European Market LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

Regulatory approval enables entry of Auryon Atherectomy System in European market LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system,

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 29, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 8, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market LATHAM, N.Y. --(BUSINESS WIRE)--May 21, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular

New data finds AlphaVac F18 85 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden LATHAM, N.Y. --(BUSINESS WIRE)--May 6, 2024-- AngioDynamics, Inc.

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 4, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 4, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 19, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 6, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and Syntrax products LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 15, 2024-- AngioDynamics, Inc.

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient Recovery LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 23, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on